hrp0092p1-418 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology (2) | ESPE2019

Epidemiology of Diagnoses of Sex Development Disorders Based on the Registry of Rare Diseases, in a Large Area of North-Eastern Italy

Guazzarotti Laura , Censi Simona , Gutierrez Joaquin , Azzolini Sara

Background: Disorders of Sex Development (DSD) are a rare disease often caused by complex genetic mechanisms, with a wide spectrum of clinical manifestations that lead to a continous evolution of the diagnostic classification. From 2002, In the Veneto Region, all DSD diagnoses have been collected thanks to the creation of a Registry for Rare diseases, including DSD.Material and Methods: We could retrospectively analyze t...

hrp0095t6 | Section | ESPE2022

Circulating GDF15 Concentrations in Girls with Low Birth Weight and Precocious Pubarche: Effects of Prolonged Metformin Treatment

Díaz Marta , Carreras-Badosa Gemma , Bassols Judit , de Zegher Francis , López- Bermejo Abel , Villarroya Francesc , Ibáñez Lourdes

Background: Low birth weight (LBW) followed by a rapid postnatal catch-up in weight predisposes individuals to a central distribution of body fat, which is reverted by metformin. Growth-and-differentiation-factor-15 (GDF15) plays an important role in the regulation of energy homeostasis, reducing food intake and lowering body weight. We aimed to assess whether GDF15 concentrations are raised by long-term metformin treatment in LBW/catch-up girls with precociou...

hrp0089mte5.1 | Gonadal function in congenital adrenal hyperplasia (CAH) | ESPE2018

Gonadal Function in Congenital Adrenal Hyperplasia (CAH)

Claahsen - van der Grinten Hedi

Congenital adrenal hyperplasia (CAH) is a group of rare congenital disorders of the adrenal cortex due to a defect in one of the enzymes involved in steroid synthesis leading to cortisol deficiency and overproduction of adrenal androgens. In the most severe forms CAH is a life threatening disease due to the risk of Addisonian and salt wasting crisis. In the last 50 years diagnostics and treatment improved significantly. Patients are treated with lifelong replacement of glucoco...

hrp0086s9.2 | Recent advances in congenital adrenal hyperplasia | ESPE2016

Recent Advances in CAH: New Approaches to Glucocorticoid Replacement

Ross Richard

Adult CAH patients have poor health outcomes and these in part relate to the method of glucocorticoid replacement in children and adults. Life-saving glucocorticoid replacement was introduced in the 1950s and the majority of children are treated with immediate release hydrocortisone whereas adults are treated with a mixture of hydrocortisone, prednisolone, prednisone and dexamethasone from one to four times daily and in circadian and reverse circadian regimens. Despite these p...

hrp0082wg3.3 | DSD | ESPE2014

Long-term Outcome of Prenatal CAH Therapy

Lajic Svetlana

Prenatal treatment of CAH has been employed since the mid 1980’s, but long-term evaluation of this experimental treatment is scarce. In utero replacement with dexamethasone suppresses the fetal adrenal and reduces the androgens that virilise the female CAH fetus. The CAH girls are thus born with normal external genitalia and avoid early genital surgery. There is however an ethical dilemma, since the treatment with DEX has to be initiated early in gestation before...

hrp0095p1-504 | GH and IGFs | ESPE2022

easypod® Augmented Reality: Usability and acceptability of a virtual reality mobile solution to support training of patients on a connected injection device

Mericq Veronica , Kariyawasam Dulanjalee , Iñiguez German , PolakVeronica Mericq Michel , Kariyawasam Dulanjalee , Iñiguez German , PolakVeronica Mericq Michel , Kariyawasam Dulanjalee , Iñiguez German , PolakVeronica Mericq Michel , Kariyawasam Dulanjalee , Iñiguez German , Polak Michel

Background: Smartphones are becoming increasingly popular and powerful across the globe, which, in turn, has provided unforeseen opportunities in the digital health space. The increased capabilities of smartphones have allowed the incorporation of Augmented Reality (AR) capabilities that merge input from their cameras with additional, augmented annotations and representations. While there has been research on the use of AR in managing paediatric diabetes,1 to ...

hrp0084p3-655 | Bone | ESPE2015

A Longitudinal, Prospective, Long-Term Registry of Patients with Hypophosphatasia

Linglart Agnes , Hogler Wolfgang , Langman Craig , Mornet Etienne , Ozono Keiichi , Rockman-Greenberg Cheryl , Seefried Lothar , Bedrosian Camille , Fujita Kenji P , Cole Alex , Kishnani Priya

Background: Hypophosphatasia (HPP) is a rare, inherited metabolic disease characterised by bone mineralisation defects and osteomalacia, and systemic manifestations, including seizures, respiratory insufficiency, muscle weakness, nephrocalcinosis, and pain. The biochemical hallmark of HPP is low serum alkaline phosphatase activity, resulting from loss-of-function mutations in the gene encoding tissue non-specific alkaline phosphatase. HPP presents a broad spectrum of disease s...

hrp0097fc14.2 | Late Breaking | ESPE2023

New Reference Values for Thyroid Volume by Ultrasound in German Children and Adolescents Under Iodine-Sufficient Conditions From a Nationwide Study

Hirtz Raphael , Thamm Roma , Kuhnert Ronny , Grasemann Corinna

Introduction: Reliable reference values for thyroid ultrasound measurements are essential to effectively guide individual diagnostics and direct health care measures at the population level, such as iodine fortification programs. However, the latest reference values for total thyroid volume (Tvol) provided by the WHO in 2004 are only applicable to the 6 to 12-year-old age group. Moreover, these values are derived from countries with a long history of iodine su...

hrp0092p1-214 | GH and IGFs (1) | ESPE2019

The European Increlex® Growth Forum Database (EU-IGFD) Registry: Do Treatment Practices Differ Between European Countries?

Bang Peter , Polak Michel , Woelfle Joachim , Perrot Valérie , Sert Caroline

Background: In the European Union, Increlex® (mecasermin) is approved for the treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (SPIGFD).Methods: The European Increlex® Growth Forum Database (EU-IGFD) registry (NCT00903110) is an ongoing, multicentre, open-label, observational study monitoring the safety and efficacy of mecasermin in childr...

hrp0086s9.3 | Recent advances in congenital adrenal hyperplasia | ESPE2016

Recent Advances in CAH: Treatments Saving GC Exposure

Auchus Richard

Background: Glucocorticoid therapy in 21-hydroxylase deficiency (congenital adrenal hyperplasia, CAH) both replaces the cortisol deficiency and reduces adrenal androgen production. Androgen control, however, often requires supraphysiologic and/or nocturnal glucocorticoid exposure. Chronic treatment in this manner contributes to long-term complications observed in CAH cohorts, including high rates of obesity, low bone density, glucose intolerance, skin fragility, and excess mor...